United Therapeutics price target lowered to $285 from $295 at Ladenburg

Ladenburg analyst Matthew Kaplan lowered the firm’s price target on United Therapeutics to $285 from $295 and keeps a Buy rating on the shares following the Q4 results. The analyst expects the growth of treprostinil-based products to largely be driven by the growing market potential for Tyvaso. The decreased price target reflects updated projections for United’s pipeline programs.